MARKET

ONCS

ONCS

OncoSec Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.568
-0.062
-1.71%
Opening 12:52 06/16 EDT
OPEN
3.610
PREV CLOSE
3.630
HIGH
3.694
LOW
3.530
VOLUME
71.14K
TURNOVER
--
52 WEEK HIGH
8.16
52 WEEK LOW
1.840
MARKET CAP
139.81M
P/E (TTM)
-2.0891
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 20h ago
OncoSec to Present at the Raymond James Human Health Innovation Conference
and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at the Raymond James Human Health Innovation Conference being held virtually – , 2021.
PR Newswire - PRF · 05/27 12:30
OncoSec Medical Granted U.S. Patent Titled 'Method and device for treating microscopic residual tumors remaining in tissues following surgical resection'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=32&f=G&l=50&co1=AND&d=PTXT&s1=%22**%22&OS=
Benzinga · 05/18 14:03
BRIEF-OncoSec Appoints Robert Schinagl As VP Of Program And Alliance Management
reuters.com · 05/17 13:16
OncoSec Appoints Robert M. Schinagl, Ph.D. as Vice President of Program and Alliance Management
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Robert M. Schinagl, Ph.D., a biotech industry veteran with over 20 years of experience, as Vice President of Program and Alliance Management, effecti...
PR Newswire · 05/17 12:30
Metastatic Melanoma Drug Market Trends, Drivers, and Growth Prospects until 2021 - 2028 By Ameco Research
pune, India, Sun, 09 May 2021 23:48:59 / Comserve Inc. / -- The global Metastatic Melanoma Drug market is segmented by company, region (country), by Type,...
Comserve · 05/10 03:50
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Benzinga · 05/07 20:32
Merkel Cell Carcinoma Treatment Market Application, Product, Sales and Forecast 2021-2028 Report By Ameco Research
pune, India, Thu, 06 May 2021 22:54:06 / Comserve Inc. / -- The global Merkel Cell Carcinoma Treatment market is segmented by company, region (country), by...
Comserve · 05/07 03:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONCS. Analyze the recent business situations of OncoSec Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONCS stock price target is 9.75 with a high estimate of 11.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 49
Institutional Holdings: 7.73M
% Owned: 19.72%
Shares Outstanding: 39.19M
TypeInstitutionsShares
Increased
17
2.75M
New
10
954.58K
Decreased
4
85.58K
Sold Out
6
256.15K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.58%
Pharmaceuticals & Medical Research
-0.06%
Key Executives
Chairman/Independent Director
Margaret Dalesandro
President/Chief Executive Officer/Director
Daniel O'Connor
Chief Operating Officer
Brian Leuthner
Chief Accounting Officer/Controller
Robert DelAversano
Vice President - Business Development
Joe Smith
Director
Joon Kim
Director
Kevin Smith
Director
Yuhang Zhao
Director
Chao Zhou
Independent Director
James DeMesa
Independent Director
Herbert Lyerly
Independent Director
Robert Ward
No Data
About ONCS
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s core platform technology, ImmunoPulse, is a drug-device therapeutic modality comprised of intratumoral electroporation (EP) delivery device. The ImmunoPulse platform is designed to deliver plasmid deoxyribonucleic acid (DNA)-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse device can be adapted to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. The Company’s lead product candidate is a DNA-encoded interleukin-12 (IL-12) called tavokinogene telseplasmid (TAVO).

Webull offers kinds of OncoSec Medical Inc stock information, including NASDAQ:ONCS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCS stock methods without spending real money on the virtual paper trading platform.